Ulcerative terminal ileitis after BCG therapy for bladder carcinoma.
OBJECTIVE
We evaluated the aetiology of ulcerative ileitis in a 77-year-old patient receiving BCG therapy for recurring bladder carcinoma.


RESULTS
Histological examination, laboratory data and the clinical history allowed us to exclude a classical cause such as Crohn's disease, tuberculosis or ischaemia. The important locoregional reaction suggests a BCG ileitis of the terminal ileum. Intestinal BCG ileitis has been exceptionally described after BCG vaccination.


CONCLUSIONS
Our observation of ulcerative ileitis indicates that a digestive tract location is possible as a reaction to BCG therapy.
Satgé
D
D
Laboratoire d'Anatomie Pathologique, Centre Hospitalier, Tulle, France. daniel.satge@ch-tulle.fr
Pommepuy
I
I
Hassan
T
T
Goburdhun
J
J
Flejou
J-F
JF
D000283:Administration, Intravesical; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy; D003424:Crohn Disease / Q000209:etiology* / Q000473:pathology*; D003937:Diagnosis, Differential; D006801:Humans; D007079:Ileitis / Q000209:etiology* / Q000473:pathology*; D008297:Male; D014456:Ulcer / Q000209:etiology / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
D001500:BCG Vaccine